{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T15:58:33Z","timestamp":1789401513908,"version":"build-2803163510"},"reference-count":96,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,11]],"date-time":"2020-09-11T00:00:00Z","timestamp":1599782400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Advanced Research"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.jare.2020.09.006","type":"journal-article","created":{"date-parts":[[2020,10,3]],"date-time":"2020-10-03T01:49:18Z","timestamp":1601689758000},"page":"45-54","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"special_numbering":"C","title":["PD-1\/PDL-1 Inhibitors and Cardiotoxicity; Molecular, Etiological and Management Outlines"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7928-2343","authenticated-orcid":false,"given":"Mohammed","family":"Safi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyat","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Al-Azab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-long","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Al-radhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Al-danakh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Shopit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiwei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.jare.2020.09.006_b0005","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nrd3500","article-title":"Cancer immunotherapy\u2013revisited","volume":"10","author":"Lesterhuis","year":"2011","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"10.1016\/j.jare.2020.09.006_b0010","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.013757","article-title":"Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment","volume":"9","author":"Palaskas","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"10.1016\/j.jare.2020.09.006_b0015","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13045-019-0779-5","article-title":"Immune checkpoint inhibitors of PD-L1 as cancer therapeutics","volume":"12","author":"Akinleye","year":"2019","journal-title":"J Hematol Oncol"},{"issue":"12","key":"10.1016\/j.jare.2020.09.006_b0020","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.jare.2020.09.006_b0025","first-page":"86","article-title":"A review of cancer immunotherapy toxicity","volume":"70","author":"Kennedy","year":"2020","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"10.1016\/j.jare.2020.09.006_b0030","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1093\/cvr\/cvaa222","article-title":"Cardiac dysfunction in cancer patients: beyond direct cardiomyocyte damage of anticancer drugs: novel cardio-oncology insights from the joint 2019 meeting of the ESC Working Groups of Myocardial Function and Cellular Biology of the Heart","volume":"116","author":"Tocchetti","year":"2020","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jare.2020.09.006_b0035","article-title":"Cardiotoxicity from immune checkpoint inhibitors","volume":"25","author":"Michel","year":"2019","journal-title":"Int J Cardiol Heart Vasc"},{"issue":"6","key":"10.1016\/j.jare.2020.09.006_b0040","doi-asserted-by":"crossref","DOI":"10.3390\/cells9061376","article-title":"PD-1: its discovery, involvement in cancer immunotherapy, and beyond","volume":"9","author":"Ishida","year":"2020","journal-title":"Cells"},{"issue":"5502","key":"10.1016\/j.jare.2020.09.006_b0045","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1126\/science.291.5502.319","article-title":"Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice","volume":"291","author":"Nishimura","year":"2001","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.jare.2020.09.006_b0050","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1093\/intimm\/8.5.765","article-title":"Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes","volume":"8","author":"Agata","year":"1996","journal-title":"Int Immunol"},{"issue":"10","key":"10.1016\/j.jare.2020.09.006_b0055","doi-asserted-by":"crossref","first-page":"5538","DOI":"10.4049\/jimmunol.169.10.5538","article-title":"Expression of programmed death 1 ligands by murine T cells and APC","volume":"169","author":"Yamazaki","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.jare.2020.09.006_b0060","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu Rev Immunol"},{"issue":"5","key":"10.1016\/j.jare.2020.09.006_b0065","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.4049\/jimmunol.1003208","article-title":"IFN-alpha directly promotes programmed cell death-1 transcription and limits the duration of T cell-mediated immunity","volume":"186","author":"Terawaki","year":"2011","journal-title":"J Immunol"},{"issue":"7","key":"10.1016\/j.jare.2020.09.006_b0070","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.4049\/jimmunol.181.7.4832","article-title":"NFATc1 regulates PD-1 expression upon T cell activation","volume":"181","author":"Oestreich","year":"2008","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.jare.2020.09.006_b0075","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.immuni.2014.10.013","article-title":"The transcription factor FoxO1 sustains expression of the inhibitory receptor PD-1 and survival of antiviral CD8(+) T cells during chronic infection","volume":"41","author":"Staron","year":"2014","journal-title":"Immunity"},{"issue":"7","key":"10.1016\/j.jare.2020.09.006_b0080","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/ni.2046","article-title":"Transcription factor T-bet represses expression of the inhibitory receptor PD-1 and sustains virus-specific CD8+ T cell responses during chronic infection","volume":"12","author":"Kao","year":"2011","journal-title":"Nat Immunol"},{"issue":"13","key":"10.1016\/j.jare.2020.09.006_b0085","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1084\/jem.20090847","article-title":"PD-L1 regulates the development, maintenance, and function of induced regulatory T cells","volume":"206","author":"Francisco","year":"2009","journal-title":"J Exp Med"},{"issue":"12","key":"10.1016\/j.jare.2020.09.006_b0090","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/70932","article-title":"B7\u2013H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion","volume":"5","author":"Dong","year":"1999","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.jare.2020.09.006_b0095","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/85330","article-title":"PD-L2 is a second ligand for PD-1 and inhibits T cell activation","volume":"2","author":"Latchman","year":"2001","journal-title":"Nat Immunol"},{"issue":"11","key":"10.1016\/j.jare.2020.09.006_b0100","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/s41401-018-0062-2","article-title":"Cancer immune checkpoint blockade therapy and its associated autoimmune cardiotoxicity","volume":"39","author":"Zhang","year":"2018","journal-title":"Acta Pharmacol Sin"},{"issue":"5","key":"10.1016\/j.jare.2020.09.006_b0105","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.tcm.2012.07.005","article-title":"Role of impaired central tolerance to alpha-myosin in inflammatory heart disease","volume":"22","author":"Lv","year":"2012","journal-title":"Trends Cardiovasc Med"},{"issue":"1","key":"10.1016\/j.jare.2020.09.006_b0110","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/sj.icb.7100141","article-title":"What do we know about the mechanisms of elimination of autoreactive T and B cells and what challenges remain","volume":"86","author":"Strasser","year":"2008","journal-title":"Immunol Cell Biol"},{"issue":"1","key":"10.1016\/j.jare.2020.09.006_b0115","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/ni.1817","article-title":"Mechanisms maintaining peripheral tolerance","volume":"11","author":"Mueller","year":"2010","journal-title":"Nat Immunol"},{"issue":"5238","key":"10.1016\/j.jare.2020.09.006_b0120","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1126\/science.270.5238.985","article-title":"Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4","volume":"270","author":"Waterhouse","year":"1995","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.jare.2020.09.006_b0125","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.4049\/jimmunol.181.4.2513","article-title":"Programmed death ligand 1 regulates a critical checkpoint for autoimmune myocarditis and pneumonitis in MRL mice","volume":"181","author":"Lucas","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.jare.2020.09.006_b0130","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3389\/fcvm.2019.00003","article-title":"Cardiac complications in immune checkpoint inhibition therapy","volume":"6","author":"Tajiri","year":"2019","journal-title":"Front Cardiovasc Med"},{"issue":"4","key":"10.1016\/j.jare.2020.09.006_b0135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0124059","article-title":"Upregulation of programmed death-1 and its ligand in cardiac injury models: interaction with GADD153","volume":"10","author":"Baban","year":"2015","journal-title":"PLoS ONE"},{"issue":"7","key":"10.1016\/j.jare.2020.09.006_b0140","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s11936-019-0731-6","article-title":"Cardiotoxicity of immune checkpoint inhibitors","volume":"21","author":"Zhang","year":"2019","journal-title":"Curr Treat Options Cardiovasc Med"},{"issue":"4","key":"10.1016\/j.jare.2020.09.006_b0145","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2017-000247","article-title":"Cardiotoxicity of immune checkpoint inhibitors","volume":"2","author":"Varricchi","year":"2017","journal-title":"ESMO Open"},{"issue":"13","key":"10.1016\/j.jare.2020.09.006_b0150","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1016\/j.jacc.2019.07.079","article-title":"Cardiovascular toxicities of immune checkpoint inhibitors: JACC review topic of the week","volume":"74","author":"Ball","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"10.1016\/j.jare.2020.09.006_b0155","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.jare.2020.09.006_b0160","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jare.2020.09.006_b0165","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.carpath.2017.06.009","article-title":"Winning the battle, but losing the war: mechanisms and morphology of cancer-therapy-associated cardiovascular toxicity","volume":"30","author":"Glass","year":"2017","journal-title":"Cardiovasc Pathol"},{"issue":"12","key":"10.1016\/j.jare.2020.09.006_b0170","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/nm955","article-title":"Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice","volume":"9","author":"Okazaki","year":"2003","journal-title":"Nat Med"},{"issue":"15","key":"10.1016\/j.jare.2020.09.006_b0175","doi-asserted-by":"crossref","first-page":"4735","DOI":"10.1158\/1078-0432.CCR-18-4083","article-title":"Myocarditis in cynomolgus monkeys following treatment with immune checkpoint inhibitors","volume":"25","author":"Ji","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"18","key":"10.1016\/j.jare.2020.09.006_b0180","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1161\/CIRCULATIONAHA.107.709360","article-title":"Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8+ T-cell mediated injury in the heart","volume":"116","author":"Grabie","year":"2007","journal-title":"Circulation"},{"issue":"7528","key":"10.1016\/j.jare.2020.09.006_b0185","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nature13904","article-title":"MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer","volume":"515","author":"Powles","year":"2014","journal-title":"Nature"},{"issue":"7528","key":"10.1016\/j.jare.2020.09.006_b0190","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.jare.2020.09.006_b0195","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s40425-016-0166-5","article-title":"Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction","volume":"4","author":"Kanz","year":"2016","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jare.2020.09.006_b0200","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jaut.2013.05.004","article-title":"The heart of the matter: protection of the myocardium from T cells","volume":"45","author":"Lichtman","year":"2013","journal-title":"J Autoimmun"},{"issue":"10","key":"10.1016\/j.jare.2020.09.006_b0205","doi-asserted-by":"crossref","first-page":"4876","DOI":"10.4049\/jimmunol.1200389","article-title":"PD-1 protects against inflammation and myocyte damage in T cell-mediated myocarditis","volume":"188","author":"Tarrio","year":"2012","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.jare.2020.09.006_b0210","doi-asserted-by":"crossref","first-page":"15998","DOI":"10.1038\/s41598-017-16147-1","article-title":"T helper cells with specificity for an antigen in cardiomyocytes promote pressure overload-induced progression from hypertrophy to heart failure","volume":"7","author":"Groschel","year":"2017","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.jare.2020.09.006_b0215","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/intimm\/dxq026","article-title":"PD-1 deficiency results in the development of fatal myocarditis in MRL mice","volume":"22","author":"Wang","year":"2010","journal-title":"Int Immunol"},{"issue":"9","key":"10.1016\/j.jare.2020.09.006_b0220","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1016\/S1470-2045(18)30457-1","article-title":"Immune checkpoint inhibitors and cardiovascular toxicity","volume":"19","author":"Lyon","year":"2018","journal-title":"Lancet Oncol"},{"issue":"Suppl 35","key":"10.1016\/j.jare.2020.09.006_b0225","doi-asserted-by":"crossref","first-page":"S4323","DOI":"10.21037\/jtd.2018.10.07","article-title":"Heart failure in cancer: role of checkpoint inhibitors","volume":"10","author":"Delgobo","year":"2018","journal-title":"J Thorac Dis"},{"issue":"16","key":"10.1016\/j.jare.2020.09.006_b0230","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"10.1016\/j.jare.2020.09.006_b0235","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/eurheartj\/ehaa051","article-title":"Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis","volume":"41","author":"Zhang","year":"2020","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.jare.2020.09.006_b0240","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/s41569-020-0342-7","article-title":"Important distinction between acute coronary syndromes and Takotsubo syndrome","volume":"17","author":"Marafioti","year":"2020","journal-title":"Nat Rev Cardiol"},{"issue":"8","key":"10.1016\/j.jare.2020.09.006_b0245","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.jcmg.2017.11.036","article-title":"Takotsubo-like syndrome in cancer patients treated with immune checkpoint inhibitors","volume":"11","author":"Ederhy","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jare.2020.09.006_b0250","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s40425-016-0152-y","article-title":"Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy","volume":"4","author":"Heinzerling","year":"2016","journal-title":"J Immunother Cancer"},{"issue":"Suppl 1","key":"10.1016\/j.jare.2020.09.006_b0255","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.21037\/tlcr.2017.12.10","article-title":"Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a meta-analysis","volume":"6","author":"Hu","year":"2017","journal-title":"Transl Lung Cancer Res"},{"issue":"4","key":"10.1016\/j.jare.2020.09.006_b0260","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.jtho.2017.12.002","article-title":"PD-1 modulates radiation-induced cardiac toxicity through cytotoxic T lymphocytes","volume":"13","author":"Du","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jare.2020.09.006_b0265","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3389\/fimmu.2018.00315","article-title":"Checks and balances in autoimmune vasculitis","volume":"9","author":"Hid Cadena","year":"2018","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.jare.2020.09.006_b0270","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/ckj\/sfz029","article-title":"T-lymphocyte in ANCA-associated vasculitis: what do we know? A pathophysiological and therapeutic approach","volume":"12","author":"Martinez Valenzuela","year":"2019","journal-title":"Clin Kidney J"},{"issue":"5","key":"10.1016\/j.jare.2020.09.006_b0275","doi-asserted-by":"crossref","first-page":"H1052","DOI":"10.1152\/ajpheart.00024.2017","article-title":"Immune checkpoint dysfunction in large and medium vessel vasculitis","volume":"312","author":"Watanabe","year":"2017","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"4","key":"10.1016\/j.jare.2020.09.006_b0280","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S1470-2045(18)30107-4","article-title":"Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial","volume":"19","author":"Choueiri","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jare.2020.09.006_b0285","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ejca.2016.02.024","article-title":"Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy","volume":"60","author":"Zimmer","year":"2016","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.jare.2020.09.006_b0290","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.jtho.2018.02.008","article-title":"PD-(L)1 Inhibition and cardiac damage: a relevant toxicity?","volume":"13","author":"De Ruysscher","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"10124","key":"10.1016\/j.jare.2020.09.006_b0295","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","article-title":"Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis","volume":"391","author":"Moslehi","year":"2018","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.jare.2020.09.006_b0300","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"issue":"21","key":"10.1016\/j.jare.2020.09.006_b0305","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1161\/CIRCULATIONAHA.117.030571","article-title":"Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity","volume":"136","author":"Escudier","year":"2017","journal-title":"Circulation"},{"issue":"20","key":"10.1016\/j.jare.2020.09.006_b0310","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jare.2020.09.006_b0315","first-page":"812","article-title":"Late-onset fulminant myocarditis with immune checkpoint inhibitor nivolumab","volume":"34","author":"Yamaguchi","year":"2018","journal-title":"Can J Cardiol"},{"issue":"8","key":"10.1016\/j.jare.2020.09.006_b0320","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1634\/theoncologist.2018-0130","article-title":"Immune checkpoint inhibitor-associated myocarditis","volume":"23","author":"Ganatra","year":"2018","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.jare.2020.09.006_b0325","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.jtho.2019.02.026","article-title":"Immune checkpoint inhibitor-associated pericarditis","volume":"14","author":"Altan","year":"2019","journal-title":"J Thorac Oncol"},{"issue":"4","key":"10.1016\/j.jare.2020.09.006_b0330","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11040580","article-title":"Sequential blockade of PD-1 and PD-L1 causes fulminant cardiotoxicity-from case report to mouse model validation","volume":"11","author":"Liu","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jare.2020.09.006_b0335","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ejca.2018.06.021","article-title":"Fatal autoimmune myocarditis with anti-PD-L1 and tyrosine kinase inhibitor therapy for renal cell cancer","volume":"101","author":"Berner","year":"2018","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.jare.2020.09.006_b0340","doi-asserted-by":"crossref","first-page":"607","DOI":"10.5414\/CP203448","article-title":"Fatal outcome of atezolizumab in a patient with immune-mediated pneumonitis, thrombocytopenia, and cardiac dysfunction: A case report","volume":"57","author":"Li","year":"2019","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.jare.2020.09.006_b0345","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.3389\/fphar.2019.01350","article-title":"Immune Checkpoint inhibitor-associated cardiotoxicity: current understanding on its mechanism","volume":"10","author":"Zhou","year":"2019","journal-title":"Diagn Manage Front Pharmacol"},{"issue":"36","key":"10.1016\/j.jare.2020.09.006_b0350","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur Heart J"},{"issue":"33","key":"10.1016\/j.jare.2020.09.006_b0355","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/eht210","article-title":"Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases","volume":"34","author":"Caforio","year":"2013","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.jare.2020.09.006_b0360","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","volume":"37","author":"Roffi","year":"2016","journal-title":"Eur Heart J"},{"issue":"38","key":"10.1016\/j.jare.2020.09.006_b0365","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.jare.2020.09.006_b0370","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jacc.2019.11.049","article-title":"Global longitudinal strain and cardiac events in patients with immune checkpoint inhibitor-related myocarditis","volume":"75","author":"Awadalla","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.jare.2020.09.006_b0375","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s11886-019-1158-0","article-title":"Assessment of myocarditis: cardiac MR, PET\/CT, or PET\/MR?","volume":"21","author":"Chen","year":"2019","journal-title":"Curr Cardiol Rep"},{"issue":"8","key":"10.1016\/j.jare.2020.09.006_b0380","doi-asserted-by":"crossref","first-page":"725","DOI":"10.2217\/imt-2018-0118","article-title":"Cardiotoxicity with immune system targeting drugs: a meta-analysis of anti-PD\/PD-L1 immunotherapy randomized clinical trials","volume":"11","author":"Rahouma","year":"2019","journal-title":"Immunotherapy"},{"issue":"1","key":"10.1016\/j.jare.2020.09.006_b0385","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"issue":"26","key":"10.1016\/j.jare.2020.09.006_b0390","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.jare.2020.09.006_b0395","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jare.2020.09.006_b0400","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.5114\/amsad.2017.72531","article-title":"A unique reason for coronary spasm causing temporary ST elevation myocardial infarction (inferior STEMI) - systemic inflammatory response syndrome after use of pembrolizumab","volume":"2","author":"Nykl","year":"2017","journal-title":"Arch Med Sci Atheroscler Dis"},{"issue":"2","key":"10.1016\/j.jare.2020.09.006_b0405","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-PD-1 therapy in patients with advanced melanoma and pre-existing autoimmune disorders or major toxicity with ipilimumab","volume":"28","author":"Menzies","year":"2017","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.jare.2020.09.006_b0410","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1007\/s10067-018-4177-0","article-title":"Vasculitis associated with immune checkpoint inhibitors-a systematic review","volume":"37","author":"Daxini","year":"2018","journal-title":"Clin Rheumatol"},{"issue":"4","key":"10.1016\/j.jare.2020.09.006_b0415","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/annonc\/mdv623","article-title":"Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper","volume":"27","author":"Champiat","year":"2016","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.jare.2020.09.006_b0420","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1159\/000498985","article-title":"Cardiac toxicity associated with immune checkpoint inhibitors: case series and review of the literature","volume":"12","author":"Agrawal","year":"2019","journal-title":"Case Rep Oncol"},{"issue":"8","key":"10.1016\/j.jare.2020.09.006_b0425","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.healun.2010.05.034","article-title":"The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients","volume":"29","author":"Costanzo","year":"2010","journal-title":"J Heart Lung Transplant"},{"issue":"1","key":"10.1016\/j.jare.2020.09.006_b0430","first-page":"92","article-title":"Immune checkpoint inhibitor-associated myocarditis: a new challenge for cardiologists","volume":"34","author":"Frigeri","year":"2018","journal-title":"Can J Cardiol"},{"issue":"10","key":"10.1016\/j.jare.2020.09.006_b0435","doi-asserted-by":"crossref","first-page":"807","DOI":"10.7326\/0003-4819-138-10-200305200-00008","article-title":"Case reports of heart failure after therapy with a tumor necrosis factor antagonist","volume":"138","author":"Kwon","year":"2003","journal-title":"Ann Intern Med"},{"issue":"7","key":"10.1016\/j.jare.2020.09.006_b0440","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/CJI.0000000000000239","article-title":"Autoimmune myocarditis caused by immune checkpoint inhibitors treated with antithymocyte globulin","volume":"41","author":"Jain","year":"2018","journal-title":"J Immunother"},{"issue":"3","key":"10.1016\/j.jare.2020.09.006_b0445","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.healun.2010.11.003","article-title":"Report from a consensus conference on antibody-mediated rejection in heart transplantation","volume":"30","author":"Kobashigawa","year":"2011","journal-title":"J Heart Lung Transplant"},{"issue":"11","key":"10.1016\/j.jare.2020.09.006_b0450","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1111\/j.1600-6143.2005.01074.x","article-title":"Antibody-mediated rejection in human cardiac allografts: evaluation of immunoglobulins and complement activation products C4d and C3d as markers","volume":"5","author":"Rodriguez","year":"2005","journal-title":"Am J Transplant"},{"issue":"11","key":"10.1016\/j.jare.2020.09.006_b0455","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1182\/blood.V85.11.3058.bloodjournal85113058","article-title":"Intensive immunosuppression with antithymocyte globulin and cyclosporine as treatment for severe acquired aplastic anemia","volume":"85","author":"Rosenfeld","year":"1995","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jare.2020.09.006_b0460","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1038\/bjc.2017.253","article-title":"Successful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy","volume":"117","author":"Tay","year":"2017","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.jare.2020.09.006_b0465","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11936-017-0532-8","article-title":"Cardiovascular complications associated with novel cancer immunotherapies","volume":"19","author":"Jain","year":"2017","journal-title":"Curr Treat Options Cardiovasc Med"},{"issue":"3","key":"10.1016\/j.jare.2020.09.006_b0470","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1093\/ajcp\/aqx056","article-title":"Therapeutic plasma exchange and its impact on drug levels: an ACLPS critical review","volume":"148","author":"Cheng","year":"2017","journal-title":"Am J Clin Pathol"},{"issue":"24","key":"10.1016\/j.jare.2020.09.006_b0475","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMc1901677","article-title":"Abatacept for severe immune checkpoint inhibitor-associated myocarditis","volume":"380","author":"Salem","year":"2019","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.jare.2020.09.006_b0480","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1056\/NEJMc1903064","article-title":"Alemtuzumab for immune-related myocarditis due to PD-1 therapy","volume":"380","author":"Esfahani","year":"2019","journal-title":"N Engl J Med"}],"container-title":["Journal of Advanced Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2090123220302150?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2090123220302150?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:50:11Z","timestamp":1761857411000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2090123220302150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":96,"alternative-id":["S2090123220302150"],"URL":"https:\/\/doi.org\/10.1016\/j.jare.2020.09.006","relation":{},"ISSN":["2090-1232"],"issn-type":[{"value":"2090-1232","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PD-1\/PDL-1 Inhibitors and Cardiotoxicity; Molecular, Etiological and Management Outlines","name":"articletitle","label":"Article Title"},{"value":"Journal of Advanced Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jare.2020.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V. on behalf of Cairo University.","name":"copyright","label":"Copyright"}]}}